153 related articles for article (PubMed ID: 1902397)
1. Cytotoxic and noncytotoxic mechanisms involved in the in vitro anti-leukaemia effects of T cell clones established from a chronic myelogenous leukaemia patient during treatment in vivo with interferon alpha.
Pawelec G; Reutter M; Owsianowsky M; Rehbein A; Busch FW
Cancer Immunol Immunother; 1991; 33(1):54-60. PubMed ID: 1902397
[TBL] [Abstract][Full Text] [Related]
2. Cellular and cytokine-mediated effects of CD4-positive lymphocyte lines generated in vitro against chronic myelogenous leukemia.
Jiang YZ; Barrett AJ
Exp Hematol; 1995 Oct; 23(11):1167-72. PubMed ID: 7556526
[TBL] [Abstract][Full Text] [Related]
3. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon.
Faber LM; van Luxemburg-Heijs SA; Rijnbeek M; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 1996 Feb; 2(1):31-6. PubMed ID: 9078352
[TBL] [Abstract][Full Text] [Related]
4. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
[TBL] [Abstract][Full Text] [Related]
5. Recognition of chronic myelogenous leukaemia cells by autologous T lymphocytes primed in vitro against the patient's dendritic cells.
Müller L; Provenzani C; Faul C; Pawelec G
Br J Haematol; 2001 Mar; 112(3):740-8. PubMed ID: 11260079
[TBL] [Abstract][Full Text] [Related]
6. Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T-cells stimulatory activity by IFN-alpha.
Wang C; Al-Omar HM; Radvanyi L; Banerjee A; Bouman D; Squire J; Messner HA
Exp Hematol; 1999 Jul; 27(7):1176-84. PubMed ID: 10390193
[TBL] [Abstract][Full Text] [Related]
7. Regulation of normal myelopoiesis and chronic myelogenous leukaemia cell proliferation through a non-cytotoxic mechanism by a gamma/delta T cell clone.
Pawelec G; Sayers T; Busch FW
Immunol Lett; 1989 Sep; 22(3):199-204. PubMed ID: 2530164
[TBL] [Abstract][Full Text] [Related]
8. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture.
Cervantes F; Pierson BA; McGlave PB; Verfaillie CM; Miller JS
Blood; 1996 Mar; 87(6):2476-85. PubMed ID: 8630414
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.
Nieda M; Nicol A; Kikuchi A; Kashiwase K; Taylor K; Suzuki K; Tadokoro K; Juji T
Blood; 1998 Feb; 91(3):977-83. PubMed ID: 9446659
[TBL] [Abstract][Full Text] [Related]
10. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia.
Selleri C; Sato T; Del Vecchio L; Luciano L; Barrett AJ; Rotoli B; Young NS; Maciejewski JP
Blood; 1997 Feb; 89(3):957-64. PubMed ID: 9028327
[TBL] [Abstract][Full Text] [Related]
11. Helper and cytotoxic lymphocyte responses to chronic myeloid leukaemia: implications for adoptive immunotherapy with T cells.
Lewalle P; Hensel N; Guimaraes A; Couriel D; Jiang Y Z; Mavroudis D; Barrett AJ
Br J Haematol; 1996 Mar; 92(3):587-94. PubMed ID: 8616022
[TBL] [Abstract][Full Text] [Related]
12. Serum-free culture of dendritic cells from patients with chronic myeloid leukemia in vitro and estimation of their cytotoxicity.
Zhao W; Xing P; Wei X; Wang T; Yang D; Li M
Chin Med J (Engl); 2002 Sep; 115(9):1296-300. PubMed ID: 12411098
[TBL] [Abstract][Full Text] [Related]
13. Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukaemia after in vivo treatment with interferon-alpha (Wellferon).
Pawelec G; Schneider E; Ehninger G; Rehbein A; Schmidt H
Cancer Immunol Immunother; 1989; 29(1):63-6. PubMed ID: 2785001
[TBL] [Abstract][Full Text] [Related]
14. Identification of T-cell clones showing expansion associated with graft-vs-leukemia effect on chronic myelogenous leukemia in vivo and in vitro.
Kondo Y; Shiobara S; Nakao S
Exp Hematol; 2001 Apr; 29(4):471-6. PubMed ID: 11301187
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
Quintarelli C; Dotti G; De Angelis B; Hoyos V; Mims M; Luciano L; Heslop HE; Rooney CM; Pane F; Savoldo B
Blood; 2008 Sep; 112(5):1876-85. PubMed ID: 18591381
[TBL] [Abstract][Full Text] [Related]
16. The progenitor cell inhibition assay to measure the anti-leukemic reactivity of T cell clones against acute and chronic myeloid leukemia.
van der Hoorn MA; van Luxemburg-Heijs SA; van Bergen CA; Bongaerts R; Willemze R; Falkenburg JH
Methods; 2003 Oct; 31(2):113-9. PubMed ID: 12957568
[TBL] [Abstract][Full Text] [Related]
17. Regulation of hematopoiesis in vitro by alloreactive natural killer cell clones.
Bellone G; Valiante NM; Viale O; Ciccone E; Moretta L; Trinchieri G
J Exp Med; 1993 Apr; 177(4):1117-25. PubMed ID: 8459206
[TBL] [Abstract][Full Text] [Related]
18. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.
Yasukawa M; Ohminami H; Kojima K; Hato T; Hasegawa A; Takahashi T; Hirai H; Fujita S
Blood; 2001 Sep; 98(5):1498-505. PubMed ID: 11520800
[TBL] [Abstract][Full Text] [Related]
19. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity.
Faber LM; van Luxemburg-Heijs SA; Veenhof WF; Willemze R; Falkenburg JH
Blood; 1995 Oct; 86(7):2821-8. PubMed ID: 7670118
[TBL] [Abstract][Full Text] [Related]
20. Recombinant interferon-alpha-2C in chronic myelogenous leukaemia: relationship of sensitivity of committed haematopoietic precursor cells in vitro (BFU-E, CFU-GM, CFU-Meg) and clinical response.
Geissler D; Gastl G; Aulitzky W; Tilg H; Gaggl S; Konwalinka G; Huber C
Leuk Res; 1990; 14(7):629-36. PubMed ID: 2388474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]